What is HC Wainwright’s Forecast for PRAX Q1 Earnings?

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) – Stock analysts at HC Wainwright lowered their Q1 2025 EPS estimates for shares of Praxis Precision Medicines in a report issued on Monday, March 3rd. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($3.18) for the quarter, down from their prior estimate of ($2.96). HC Wainwright currently has a “Buy” rating and a $105.00 target price on the stock. The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($10.22) per share. HC Wainwright also issued estimates for Praxis Precision Medicines’ Q2 2025 earnings at ($3.64) EPS, Q3 2025 earnings at ($4.15) EPS, Q4 2025 earnings at ($4.16) EPS, FY2025 earnings at ($15.13) EPS, Q1 2026 earnings at ($4.39) EPS, Q2 2026 earnings at ($4.82) EPS, Q3 2026 earnings at ($4.89) EPS, Q4 2026 earnings at ($4.90) EPS, FY2026 earnings at ($18.99) EPS, FY2027 earnings at ($15.64) EPS, FY2028 earnings at ($15.64) EPS and FY2029 earnings at $23.38 EPS.

A number of other equities analysts have also commented on PRAX. Robert W. Baird lowered their price target on shares of Praxis Precision Medicines from $117.00 to $73.00 and set an “outperform” rating on the stock in a research report on Monday. Wedbush lowered shares of Praxis Precision Medicines from a “hold” rating to a “strong sell” rating in a research report on Friday, February 28th. Needham & Company LLC lowered their price target on shares of Praxis Precision Medicines from $150.00 to $85.00 and set a “buy” rating on the stock in a research report on Monday. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Praxis Precision Medicines in a research report on Tuesday, February 11th. They set a “buy” rating and a $111.00 price target on the stock. Finally, Truist Financial lowered their price target on shares of Praxis Precision Medicines from $175.00 to $85.00 and set a “buy” rating on the stock in a research report on Monday. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. According to MarketBeat.com, Praxis Precision Medicines currently has a consensus rating of “Moderate Buy” and a consensus price target of $123.80.

Praxis Precision Medicines Stock Performance

NASDAQ PRAX opened at $36.21 on Wednesday. Praxis Precision Medicines has a 52-week low of $30.01 and a 52-week high of $91.83. The stock has a market cap of $674.88 million, a PE ratio of -3.52 and a beta of 2.65. The firm has a 50-day moving average of $74.53 and a 200-day moving average of $69.53.

Praxis Precision Medicines (NASDAQ:PRAX) last posted its earnings results on Friday, February 28th. The company reported ($2.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.76) by ($0.18). The company had revenue of $7.48 million for the quarter, compared to analyst estimates of $0.36 million. Praxis Precision Medicines had a negative return on equity of 54.86% and a negative net margin of 9,409.22%.

Institutional Investors Weigh In On Praxis Precision Medicines

Hedge funds and other institutional investors have recently made changes to their positions in the stock. US Bancorp DE increased its stake in shares of Praxis Precision Medicines by 35.9% in the 3rd quarter. US Bancorp DE now owns 2,289 shares of the company’s stock valued at $132,000 after acquiring an additional 605 shares in the last quarter. Mesirow Financial Investment Management Inc. bought a new stake in shares of Praxis Precision Medicines in the 3rd quarter valued at $231,000. CIBC Asset Management Inc increased its stake in shares of Praxis Precision Medicines by 29.2% in the 3rd quarter. CIBC Asset Management Inc now owns 248,939 shares of the company’s stock valued at $14,324,000 after acquiring an additional 56,272 shares in the last quarter. Intech Investment Management LLC bought a new stake in Praxis Precision Medicines during the 3rd quarter valued at $217,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Praxis Precision Medicines by 188.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 137,052 shares of the company’s stock valued at $7,886,000 after purchasing an additional 89,578 shares in the last quarter. 67.84% of the stock is owned by institutional investors.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.